AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Exclusion Criteria

• •1\. Refuse chemotherapy or surgery;
• •2\. Other part (e.g. peritoneum, lung, bone, brain) metastasis;
• •3\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• •4\. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP\>160mmHg or DBP\>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
• •5\. Undergone major surgery within 30 days;
• •6\. Participated in other drug related clinical trials within 4 weeks;
• •7\. Known allergy to prescription or any component of the prescription used in this study;
• •8\. With HIV, or active hepatitis (hepatitis B, hepatitis C);
• •9\. Failure to recover from treatment-related toxicity to ≤ grade 1 (adverse events such as alopecia judged by the researcher not to affect the treatment with the research drug are excluded);
• •10.Other reasons that are not suitable to participate in this study according to the researcher's judgment.